Brickell Biotech Inc

0.00 (+0.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)58.05M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.05 Million
Adjusted EPS-$0.13
See more estimates
10-Day MA$0.87
50-Day MA$0.90
200-Day MA$0.93
See more pivots

Brickell Biotech Inc Stock, NASDAQ:BBI

5777 Central Avenue, Suite 102, Boulder, Colorado 80301
United States of America
Phone: +1.720.505.4755
Number of Employees: 13


Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.